Replies to post #129725 on Biotech Values

[jb_118]

What you’re overlooking is that the overhang to MNTA’s share price from Teva’s Lovenox program is now essentially gone.

As you've pointed out, the rationale for that was never that strong anyway. It would all hang on 886. There's an unpatented way around 466.

But even if removing the overhang means a doubling of the EPS multiple you only break even if the AG chops the EPS in half. This is my concern.